NAGE
NAGE
NASDAQ · Life Sciences Tools & Services

Niagen Bioscience Inc

$3.67
-0.03 (-0.81%)
Financial Highlights (FY 2026)
Revenue
110.35M
Net Income
14.82M
Gross Margin
64.3%
Profit Margin
13.4%
Rev Growth
+21.6%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 64.3% 64.3% 42.4% 42.4%
Operating Margin 12.6% 11.3% 16.1% 15.1%
Profit Margin 13.4% 12.8% 12.4% 10.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 110.35M 90.78M 119.93M 113.70M
Gross Profit 70.93M 58.35M 50.83M 48.19M
Operating Income 13.88M 10.28M 19.31M 17.15M
Net Income 14.82M 10.97M 14.89M 12.09M
Gross Margin 64.3% 64.3% 42.4% 42.4%
Operating Margin 12.6% 11.3% 16.1% 15.1%
Profit Margin 13.4% 12.8% 12.4% 10.6%
Rev Growth +21.6% +21.6% +11.4% +12.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 133.61M 160.13M
Total Equity 171.80M 169.78M
D/E Ratio 0.78 0.94
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 14.22M 11.11M 27.61M 22.05M
Free Cash Flow 17.96M 17.42M